Go to content

Publications

415 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. GVS advice lasmiditan (Rayvow®) for the treatment of migraine

    The National Health Care Institute has assessed whether lasmiditan (Rayvow®) can be included in the Medicine Reimbursement System ...

    Report | 23-05-2023

  2. Advice on the clustering of combination products and ghost clusters in GVS (part 4)

    The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

    Report | 23-05-2023

  3. Advice on the clustering of combination products and ghost clusters in GVS (part 3)

    The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

    Report | 23-05-2023

  4. Advice on the clustering of combination products and ghost clusters in GVS (part 2)

    The Minister of Medical Care has asked the National Health Care Institute questions about the clustering of two categories of ...

    Report | 23-05-2023

  5. Package advice vitamin D

    The National Health Care Institute recommends that all colecalciferol-containing medicinal products and calcifediol be removed ...

    Report | 09-05-2023

  6. GVS advice on mifepristone (Mifegyne®) for the treatment of miscarriages

    The National Health Care Institute has tested whether mifepristone (Mifegyne®) can be included in the Medicine Reimbursement ...

    Report | 08-03-2023

  7. Conditional inclusion of orphan drugs, conditionals and exceptionals (progress report for 2022)

    At the request of the Minister of Health, Welfare and Sport (VWS), the National Health Care Institute publishes an annual report ...

    Report | 01-03-2023

  8. Package advice on the lock procedure medicinal product trastuzumab-deruxtecan (Enhertu®) for the treatment of HER2-positive breast cancer

    The National Health Care Institute has assessed whether the medicinal product trastuzumab-deruxtecan (Enhertu®) can be reimbursed ...

    Publication | 15-02-2023

  9. GVS advice icosapent-ethyl (Vazkepa®)

    The National Health Care Institute has completed its assessment whether the product icosapent-ethyl (Vazkepa®) can be included in ...

    Report | 15-02-2023

  10. GVS advice patiromer (Veltassa®) cancellation List 2 conditions

    The Minister of Health, Welfare and Sport (VWS) has adopted the recommendation of the National Health Care Institute. This means ...

    Report | 01-02-2023

Go to